Vitamin A can cut infant death risk in LDCs 15%

3 August 2008

A single, oral dose of vitamin A, given to infants shortly after birth in the developing world, can reduce their risk of death 15%, according to a study conducted by researchers at the USA's Johns Hopkins Bloomberg School of Public Health, published in the July edition of Pediatrics.

"It has long been known that vitamin A supplementation can reduce mortality in children over six months of age. Our study showed that vitamin A given at birth can also improve infant survival within the first six months of life," said lead investigator Rolf Klemm. The vitamin A was given orally to the infants within a few days of birth, usually by seven hours after delivery. The mortality rate in the active arm was 38.5 deaths per 1,000 births compared to 45.1 deaths per 1,000 births for the placebo cohort.

The trial enrolled 15,937 newborns from rural communities in northwest Bangladesh, where over 90% of babies are born at home. Half were randomly selected to receive a 50,000 IU dose of vitamin A, while the other half received a placebo. A 200,000 IU dose is recommended semi-annually for older children. While vitamin A reduced infant deaths from all causes, lives were also saved by reducing the severity of infections which are responsible for most deaths in early infancy in South Asia, Dr Klemm noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight